About the Company
We do not have any company description for Compass Therapeutics, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Compass Therapeutics, Inc.
Compass Therapeutics Inc (CMPX) Q2 2025 Earnings Call Highlights: Promising Clinical Advances ...
Compass Therapeutics Inc (CMPX) reports strong clinical outcomes and a robust cash position, setting the stage for future growth and innovation.
Compass Therapeutics Announces Proposed Public Offering
Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, ...
Compass Therapeutics, Inc. (NASDAQ:CMPX) Shares Sold by Exchange Traded ...
Compass Therapeutics, Inc. has a 52 week low of $0.77 and a 52 week high of $4.08. The firm has a market cap of $362.29 million, a price-to-earnings ratio of -6.39 and a beta of 1.41.
Compass Therapeutics Faces Financial Risks Amid Global Economic Uncertainty and Trade Tensions
Compass Therapeutics, Inc. (CMPX) has disclosed a new risk, in the Economy & Political Environment category. Compass Therapeutics, Inc. faces ...
Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Recommendation ...
Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The ...
Compass Therapeutics, Inc. (CMPX) Upgraded to Buy: What Does ... - Nasdaq
Compass Therapeutics, Inc. (CMPX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Why Compass Therapeutics, Inc. (CMPX) is Skyrocketing So Far in 2025
Compass Therapeutics, Inc. (NASDAQ:CMPX) is up 101.38% year-to-date. Overall CMPX ranks 2nd on our list of the biotech stocks that are skyrocketing so far in 2025.
What Makes Compass Therapeutics, Inc. (CMPX) a New Buy Stock
Compass Therapeutics, Inc. (CMPX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Compass Therapeutics to be Added to the Russell 2000® and Russell 3000 ...
BOSTON, June 22, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to ...
Compass Therapeutics to Participate in the Stifel Targeted Oncology ...
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s ...
Similar Companies
Loading the latest forecasts...